Rockville, Md, — April 18, 2024 — Psomagen is excited to announce our membership in the new Olink® Proteomics Certified Service Provider program. Psomagen is one of the first North American members of the service provider program certified in all of Olink's available panels, including Explore HT, Explore 3072, Target, Flex, and Focus.
Olink® panels make use of their proprietary proximity extension assay (PEA) technology, which uses antibodies with DNA tags to measure the protein profile in biofluids with high specificity. This has helped researchers make groundbreaking advancements in inflammation and disease studies. One of their newest offerings, Olink® Flex, is a highly customizable option for researchers investigating specific protein biomarkers. Researchers can follow up with an HT discovery experiment by creating a panel specific for the new biomarkers discovered. Users can select up to 21 human proteins from a list of over 200, then combine them in one biomarker panel.
Joining this program means Psomagen has completed training and testing on Olink® panels. Lori Mull, Psomagen's Proteomics Product Manager, says, "We completed this stringent concordance testing to provide our customers with full confidence that Psomagen will handle their precious samples with the utmost care."
"Expanding into proteomics was a natural progression for our business," says Matt Kramer, V.P. of Sales & Marketing at Psomagen. "As our customers explore multiomics, so too must Psomagen. Offering Olink® services enables our customers to add proteomic analysis to our existing services of genomics and transcriptomics. The Olink® portfolio supports biomarker discovery (Explore HT) through targeted analysis utilizing our existing install base of Illumina NovaSeq X Plus NGS systems and chemistries — a natural match of hardware, expertise, and capabilities."
Psomagen is a long-time provider of Olink® Proteomics services, beginning with the onboarding of Olink® Target and Explore in 2021. By adding the Olink® library of panels to our product offerings, Psomagen provides our customers with access to biomarker discovery — at the correct scale, specificity, and customization for their needs.
About Psomagen
Psomagen, formerly Macrogen, is a Contract Research Services (CRO) provider celebrating its 20th year anniversary in 2024 – over this time it has offered genomic, transcriptomic, and proteomic analysis to research programs and operations throughout North America, serving academic, pharma, biotech, government and industry. Its US-based, CAP and CLIA certified laboratories are located in Rockville, MD, New York City, NY and Boston, MA and provide genomics, transcriptomics and proteomics technologies such as short and long-read next-generation sequencing (NGS), Sanger (CE) sequencing, microarray, single-cell omics, metagenomics and microbiome, spatial biology, bioinformatics and biomarker discovery. Psomagen utilizes state-of-the-art technology from partners such as Illumina, 10X Genomics, and PacBio among others, providing services including nucleic acid or protein extraction, sample quality control, assay preparation, analysis and interpretation.
Contact
Lori Mull
Spatial Biology & Proteomics Product Manager
About Olink®
Olink® Proteomics AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink® Proteomics provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st-century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America, and Asia. Olink® Proteomics is headquartered in Uppsala, Sweden.
